Bookmark
Forward
Implications for the monitoring of patients with multiple myeloma undergoing treatment with the anti-CD38 monoclonal daratumumab.
Sally Thirkettle, Joanne Russell, Sarah Wilson, Tasneem Ganijee, Samar Kulkarni, Jim Cavet, Phillip J Monaghan
Annals of clinical biochemistry 2020 Mar
Sizes of these terms reflect their relevance to your search.
No abstract available.
Citation
Sally Thirkettle, Joanne Russell, Sarah Wilson, Tasneem Ganijee, Samar Kulkarni, Jim Cavet, Phillip J Monaghan.
Implications for the monitoring of patients with multiple myeloma undergoing treatment with the anti-CD38 monoclonal daratumumab.
Annals of clinical biochemistry.
2020 Mar;57(2):178-181
Mesh Tags
Antibodies, Monoclonal
Artifacts
Blood Protein Electrophoresis
Humans
Immunoglobulin gamma-Chains
Immunoglobulin kappa-Chains
Multiple Myeloma
Paraproteins
Retrospective Studies
Substances
Antibodies, Monoclonal
Immunoglobulin gamma-Chains
Immunoglobulin kappa-Chains
Paraproteins
daratumumab
PMID: 31791138
View Full Text